Terpenoid ID | TKC206760 | |
Chirality | TKC112784 | |
Cell line | 0 | |
Protein target | 53 | |
DiseaseNCIT | 0 | |
ORDO | 0 | |
ICD | 264 |
ID | Cell Line | Synonyms | Value | Unit | Type | NCIt | ORDO |
---|---|---|---|---|---|---|---|
TKC206760 | Caco-2 | CaCo-2; CACO-2; Caco 2; CACO 2; CACO2; CaCo2; CaCO2; Caco2; Caco-2/ATCC; Caco-II | 56000.0 | nM | IC50 | C4349 | |
TKC206760 | MDA-N | MDAN | 19953.0 | nM | GI50 | C3802 | |
TKC206760 | SN12C | SN-12C | 20845.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | ACHN | 29309.0 | nM | GI50 | C6975 | Orphanet_319298 | |
TKC206760 | NCI-H23 | NCI.H23; NCI H23; H-23; H23; NCIH23 | 15631.0 | nM | GI50 | C3512 | |
TKC206760 | UO-31 | UO.31; UO31; U031 | 14289.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | HL-60 | HL 60; HL.60 HL60; Human Leukemia-60 | 15066.0 | nM | GI50 | C9154 | Orphanet_519 |
TKC206760 | HOP-92 | HOP 92; HOP.92; HOP92; Hop92; Hopkins-92 | 27990.0 | nM | GI50 | C2926 | |
TKC206760 | SF-539 | SF-539; SF-539 BT; SF.539; SF 539 | 26002.0 | nM | GI50 | C3796 | Orphanet_251576 |
TKC206760 | DU-145 | DU-145; Du-145; DU 145; DU_145; DU.145; Duke University 145 | 29992.0 | nM | GI50 | C4863 | |
TKC206760 | Malme-3M | MALME-3M; MALME 3M; Malme-3 M; MALME.3M; Malme3M; MALME3M; Malme-3 Monolayer | 40272.0 | nM | GI50 | C3224 | |
TKC206760 | SK-MEL-5 | SK-Mel-5; SK MEL 5; SK.MEL.5; SK-MEL5; SKMel-5; SKMEL-5; SKMEL5; SKMel5; SKmel5; AA-Mel | 18281.0 | nM | GI50 | C3510 | |
TKC206760 | A498 | A498 | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | K562 | K562; K.562; K 562; KO; GM05372; GM05372E | 17378.0 | nM | GI50 | C9110 | Orphanet_521 |
TKC206760 | MOLT-4 | Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D | 21528.0 | nM | GI50 | C9142 | Orphanet_99861 |
TKC206760 | OVCAR-3 | Ovcar-3; OVCAR 3; OVCAR.3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR3; Ovcar3 | 19011.0 | nM | GI50 | C105555 | |
TKC206760 | HOP-62 | HOP 62; Hop 62; HOP.62; HOP62; Hop62; Hopkins-62 | 28184.0 | nM | GI50 | C3512 | |
TKC206760 | NCI/ADR-RES | NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR | 29242.0 | nM | GI50 | C105555 | |
TKC206760 | U-251 | U-251 MG; U-251-MG; U-251_MG; U251-MG; U251MG; U-251; U251; U251n; U251N; 251 MG; 251MG; 251 MG(6) | 21281.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | OVCAR-8 | OVCAR 8; NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 | 41305.0 | nM | GI50 | C105555 | |
TKC206760 | OVCAR-5 | OVCAR 5; NIH:OVCAR-5; OVCAR.5; OVCAR5; Ovcar5; OVCA5 | 20701.0 | nM | GI50 | C105555 | |
TKC206760 | SNB-19 | SNB.19; SNB19; Surgical Neurology Branch-19 | 24322.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | MDA-MB-231 | MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231 | 28249.0 | nM | GI50 | C5214 | |
TKC206760 | SR | SR-786; SR786 | 14622.0 | nM | GI50 | C37193 | Orphanet_300895 |
TKC206760 | TK-10 | TK.10; TK 10; TK10 | 33574.0 | nM | GI50 | C4033 | Orphanet_319276 |
TKC206760 | SW-620 | SW-620; SW 620; SW.620 | 26977.0 | nM | GI50 | C4349 | |
TKC206760 | NCI-H522 | NCI.H522; H522; H-522; NCI-522; NCI522; NCIH522 | 25468.0 | nM | GI50 | C3512 | |
TKC206760 | KM12 | KM-12; KM.12 | 24378.0 | nM | GI50 | C4910 | |
TKC206760 | M14 | M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14 | 17258.0 | nM | GI50 | C3802 | |
TKC206760 | NCI-H322M | NCI.H322M; H322M; H-322M; H-322m | 28054.0 | nM | GI50 | C2923 | |
TKC206760 | RPMI-8226 | RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson | 22856.0 | nM | GI50 | C3242 | Orphanet_29073 |
TKC206760 | OVCAR-4 | OVCAR 4; NIH:OVCAR-4; NIH:OVCAR4; OVCAR.4; OVCAR4; Ovcar4 | 31333.0 | nM | GI50 | C105555 | |
TKC206760 | LOX IMVI | LOX/IMVI; LOX IMVI; LOXIM-VI; LOXIMVI; LOX | 28907.0 | nM | GI50 | C3802 | |
TKC206760 | BT-549 | BT 549; BT.549; BT549 | 28445.0 | nM | GI50 | C4194 | |
TKC206760 | SK-MEL-2 | SK-Mel-2; SK-Mel 2; SK-mel-2; SK-MEL2; SK.MEL.2; SK Mel 2; SK MEL 2; SKMEL-2; SKMEL2; SKmel2; SK-ML2; SKml2 | 21528.0 | nM | GI50 | C3224 | |
TKC206760 | A549 | 18365.0 | nM | GI50 | C3512 | ||
TKC206760 | HCC 2998 | HCC-2998; HCC.2998; HCC 2998; Hamon Cancer Center 2998 | 19815.0 | nM | GI50 | C4349 | |
TKC206760 | SNB-75 | SNB.75; SNB75; Surgical Neurology Branch-75 | 24604.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC206760 | HCT-15 | HCT-15; HCT.15; HCT15 | 23496.0 | nM | GI50 | C4349 | |
TKC206760 | SF-268 | SF-268; SF.268; SF 268 | 35975.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | EKVX | 19953.0 | nM | GI50 | C3512 | ||
TKC206760 | MCF7 | 30200.0 | nM | GI50 | C4194 | ||
TKC206760 | PC-3 | PC3; PC.3 | 23878.0 | nM | GI50 | C4863 | |
TKC206760 | T47D | 19953.0 | nM | GI50 | C4194 | ||
TKC206760 | SK-OV-3 | SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3 | 40272.0 | nM | GI50 | C7978 | |
TKC206760 | NCI-H460 | NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460 | 18197.0 | nM | GI50 | C4450 | |
TKC206760 | UACC-62 | UACC 62; UACC.62; UACC62; University of Arizona Cell Culture-62 | 35318.0 | nM | GI50 | C3224 | |
TKC206760 | MDA-MB-435 | MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435 | 22594.0 | nM | GI50 | C3802 | |
TKC206760 | CAKI-1 | CAL 1; Centre Antoine Lacassagne-1 | 22131.0 | nM | GI50 | C3224 | |
TKC206760 | IGROV-1 | Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P | 39994.0 | nM | GI50 | C7979 | Orphanet_454723 |
TKC206760 | SF-295 | SF-295; SF.295; SF 295 | 37239.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC206760 | Hs-578T | HS 578T; Hs-578T; HS-578T; Hs_578t; Hs-578-T; HS-578-T; Hs 578.T; HS578T; Hs578T; Hs578t; HS0578T; 578T; HS578; Hs578; Homo sapiens No. 578, tumor cells | 33343.0 | nM | GI50 | C4194 | |
TKC206760 | 786-0 | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT | 31842.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | UACC-257 | UACC 257; UACC.257; UACC257; University of Arizona Cell Culture-257 | 27669.0 | nM | GI50 | C3224 | |
TKC206760 | CCRF-CEM | CCRF/CEM; CCRFCEM; CCRF.CEM; CCRF CEM; CCRF; CEM; CEM-CCRF; CEM-CCRF (CAMR); CCRF/CEM/0; CEM/0; CEM-0; CCRF-CEM/S; GM03671; GM03671C | 21878.0 | nM | GI50 | C7953 | Orphanet_99861 |
TKC206760 | NCI-H226 | NCI.H226; NCI H226; H226; H-226; HUT-226; HUT 226; NCIH226 | 37068.0 | nM | GI50 | C45662 | Orphanet_50251 |
TKC206760 | HT-29 | HT 29; HT29 | 21627.0 | nM | GI50 | C4349 | |
TKC206760 | SK-MEL-28 | SK-Mel-28; SK.MEL.28; SK-MEL 28; SK MEL-28; SK MEL 28; SK Mel 28; SKMel-28; SKMEL-28; SK-MEL28; SK-Mel28; SK Mel28; SKMEL28; SKMel28; SKmel28; SKML-28; SK28; AU-Mel; P-36; P36 | 27040.0 | nM | GI50 | C3510 | |
TKC206760 | COLO 205 | Colo 205; CoLo 205; COLO-205; Colo-205; COLO.205; Colo205; COLO205; Co 205; Colorado 205 | 23714.0 | nM | GI50 | C4349 | |
TKC206760 | RXF 393 | RXF393L; RXF-393 L; RXF-393; RXF 393; RXF.393; RXF393; RXF 393NL | 26002.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | HUVEC | HUV-EC-C; HUVEC | 75.0 | % | Activity | ||
TKC206760 | SN12C | SN-12C | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | MDA-N | MDAN | 100000.0 | nM | GI50 | C3802 | |
TKC206760 | ACHN | 100000.0 | nM | GI50 | C6975 | Orphanet_319298 | |
TKC206760 | NCI-H23 | NCI.H23; NCI H23; H-23; H23; NCIH23 | 100000.0 | nM | GI50 | C3512 | |
TKC206760 | UO-31 | UO.31; UO31; U031 | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | HL-60 | HL 60; HL.60 HL60; Human Leukemia-60 | 100000.0 | nM | GI50 | C9154 | Orphanet_519 |
TKC206760 | HOP-92 | HOP 92; HOP.92; HOP92; Hop92; Hopkins-92 | 100000.0 | nM | GI50 | C2926 | |
TKC206760 | SF-539 | SF-539; SF-539 BT; SF.539; SF 539 | 100000.0 | nM | GI50 | C3796 | Orphanet_251576 |
TKC206760 | DU-145 | DU-145; Du-145; DU 145; DU_145; DU.145; Duke University 145 | 86696.0 | nM | GI50 | C4863 | |
TKC206760 | SK-MEL-5 | SK-Mel-5; SK MEL 5; SK.MEL.5; SK-MEL5; SKMel-5; SKMEL-5; SKMEL5; SKMel5; SKmel5; AA-Mel | 100000.0 | nM | GI50 | C3510 | |
TKC206760 | Malme-3M | MALME-3M; MALME 3M; Malme-3 M; MALME.3M; Malme3M; MALME3M; Malme-3 Monolayer | 100000.0 | nM | GI50 | C3224 | |
TKC206760 | A498 | A498 | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | K562 | K562; K.562; K 562; KO; GM05372; GM05372E | 100000.0 | nM | GI50 | C9110 | Orphanet_521 |
TKC206760 | MOLT-4 | Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D | 100000.0 | nM | GI50 | C9142 | Orphanet_99861 |
TKC206760 | OVCAR-3 | Ovcar-3; OVCAR 3; OVCAR.3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR3; Ovcar3 | 100000.0 | nM | GI50 | C105555 | |
TKC206760 | NCI/ADR-RES | NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR | 100000.0 | nM | GI50 | C105555 | |
TKC206760 | HOP-62 | HOP 62; Hop 62; HOP.62; HOP62; Hop62; Hopkins-62 | 100000.0 | nM | GI50 | C3512 | |
TKC206760 | U-251 | U-251 MG; U-251-MG; U-251_MG; U251-MG; U251MG; U-251; U251; U251n; U251N; 251 MG; 251MG; 251 MG(6) | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | OVCAR-8 | OVCAR 8; NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 | 100000.0 | nM | GI50 | C105555 | |
TKC206760 | OVCAR-5 | OVCAR 5; NIH:OVCAR-5; OVCAR.5; OVCAR5; Ovcar5; OVCA5 | 100000.0 | nM | GI50 | C105555 | |
TKC206760 | MDA-MB-231 | MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231 | 100000.0 | nM | GI50 | C5214 | |
TKC206760 | SNB-19 | SNB.19; SNB19; Surgical Neurology Branch-19 | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | SR | SR-786; SR786 | 100000.0 | nM | GI50 | C37193 | Orphanet_300895 |
TKC206760 | TK-10 | TK.10; TK 10; TK10 | 100000.0 | nM | GI50 | C4033 | Orphanet_319276 |
TKC206760 | SW-620 | SW-620; SW 620; SW.620 | 100000.0 | nM | GI50 | C4349 | |
TKC206760 | NCI-H522 | NCI.H522; H522; H-522; NCI-522; NCI522; NCIH522 | 100000.0 | nM | GI50 | C3512 | |
TKC206760 | KM12 | KM-12; KM.12 | 100000.0 | nM | GI50 | C4910 | |
TKC206760 | M14 | M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14 | 100000.0 | nM | GI50 | C3802 | |
TKC206760 | NCI-H322M | NCI.H322M; H322M; H-322M; H-322m | 100000.0 | nM | GI50 | C2923 | |
TKC206760 | RPMI-8226 | RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson | 100000.0 | nM | GI50 | C3242 | Orphanet_29073 |
TKC206760 | OVCAR-4 | OVCAR 4; NIH:OVCAR-4; NIH:OVCAR4; OVCAR.4; OVCAR4; Ovcar4 | 100000.0 | nM | GI50 | C105555 | |
TKC206760 | LOX IMVI | LOX/IMVI; LOX IMVI; LOXIM-VI; LOXIMVI; LOX | 100000.0 | nM | GI50 | C3802 | |
TKC206760 | BT-549 | BT 549; BT.549; BT549 | 100000.0 | nM | GI50 | C4194 | |
TKC206760 | SK-MEL-2 | SK-Mel-2; SK-Mel 2; SK-mel-2; SK-MEL2; SK.MEL.2; SK Mel 2; SK MEL 2; SKMEL-2; SKMEL2; SKmel2; SK-ML2; SKml2 | 100000.0 | nM | GI50 | C3224 | |
TKC206760 | HCC 2998 | HCC-2998; HCC.2998; HCC 2998; Hamon Cancer Center 2998 | 100000.0 | nM | GI50 | C4349 | |
TKC206760 | A549 | 100000.0 | nM | GI50 | C3512 | ||
TKC206760 | SNB-75 | SNB.75; SNB75; Surgical Neurology Branch-75 | 44668.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC206760 | HCT-116 | HCT-116; HCT.116; HCT_116; HCT116; HCT116wt; CoCL2 | 100000.0 | nM | GI50 | C4910 | |
TKC206760 | HCT-15 | HCT-15; HCT.15; HCT15 | 100000.0 | nM | GI50 | C4349 | |
TKC206760 | SF-268 | SF-268; SF.268; SF 268 | 100000.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC206760 | EKVX | 100000.0 | nM | GI50 | C3512 | ||
TKC206760 | MCF7 | 100000.0 | nM | GI50 | C4194 | ||
TKC206760 | PC-3 | PC3; PC.3 | 100000.0 | nM | GI50 | C4863 | |
TKC206760 | SK-OV-3 | SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3 | 100000.0 | nM | GI50 | C7978 | |
TKC206760 | NCI-H460 | NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460 | 100000.0 | nM | GI50 | C4450 | |
TKC206760 | T47D | 100000.0 | nM | GI50 | C4194 | ||
TKC206760 | UACC-62 | UACC 62; UACC.62; UACC62; University of Arizona Cell Culture-62 | 100000.0 | nM | GI50 | C3224 | |
TKC206760 | MDA-MB-435 | MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435 | 100000.0 | nM | GI50 | C3802 | |
TKC206760 | CAKI-1 | CAL 1; Centre Antoine Lacassagne-1 | 100000.0 | nM | GI50 | C3224 | |
TKC206760 | IGROV-1 | Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P | 100000.0 | nM | GI50 | C7979 | Orphanet_454723 |
TKC206760 | SF-295 | SF-295; SF.295; SF 295 | 100000.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC206760 | Hs-578T | HS 578T; Hs-578T; HS-578T; Hs_578t; Hs-578-T; HS-578-T; Hs 578.T; HS578T; Hs578T; Hs578t; HS0578T; 578T; HS578; Hs578; Homo sapiens No. 578, tumor cells | 100000.0 | nM | GI50 | C4194 | |
TKC206760 | 786-0 | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC206760 | UACC-257 | UACC 257; UACC.257; UACC257; University of Arizona Cell Culture-257 | 100000.0 | nM | GI50 | C3224 | |
TKC206760 | CCRF-CEM | CCRF/CEM; CCRFCEM; CCRF.CEM; CCRF CEM; CCRF; CEM; CEM-CCRF; CEM-CCRF (CAMR); CCRF/CEM/0; CEM/0; CEM-0; CCRF-CEM/S; GM03671; GM03671C | 100000.0 | nM | GI50 | C7953 | Orphanet_99861 |
TKC206760 | NCI-H226 | NCI.H226; NCI H226; H226; H-226; HUT-226; HUT 226; NCIH226 | 100000.0 | nM | GI50 | C45662 | Orphanet_50251 |
TKC206760 | HT-29 | HT 29; HT29 | 100000.0 | nM | GI50 | C4349 | |
TKC206760 | SK-MEL-28 | SK-Mel-28; SK.MEL.28; SK-MEL 28; SK MEL-28; SK MEL 28; SK Mel 28; SKMel-28; SKMEL-28; SK-MEL28; SK-Mel28; SK Mel28; SKMEL28; SKMel28; SKmel28; SKML-28; SK28; AU-Mel; P-36; P36 | 100000.0 | nM | GI50 | C3510 | |
TKC206760 | COLO 205 | Colo 205; CoLo 205; COLO-205; Colo-205; COLO.205; Colo205; COLO205; Co 205; Colorado 205 | 100000.0 | nM | GI50 | C4349 | |
TKC206760 | RXF 393 | RXF393L; RXF-393 L; RXF-393; RXF 393; RXF.393; RXF393; RXF 393NL | 100000.0 | nM | GI50 | C9385 | Orphanet_217071 |
ID | Uniport | Pref_name | Gene name | value | unit | type |
---|---|---|---|---|---|---|
TKC206760 | Q12809 | Potassium voltage-gated channel subfamily H member 2 | KCNH2 | 50119 | nM | Potency |
TKC206760 | P10636 | Microtubule-associated protein tau | MAPT | 14125 | nM | Potency |
TKC206760 | P11473 | Vitamin D3 receptor | VDR | 8913 | nM | Potency |
TKC206760 | P11473 | Vitamin D3 receptor | VDR | 6 | % | Activity |
TKC206760 | P11473 | Vitamin D3 receptor | VDR | 330 | nM | Kd |
TKC206760 | Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | 34436 | nM | Potency |
TKC206760 | P18031 | Tyrosine-protein phosphatase non-receptor type 1 | PTPN1 | 12740 | nM | IC50 |
TKC206760 | P17706 | Tyrosine-protein phosphatase non-receptor type 2 | PTPN2 | 20450 | nM | IC50 |
TKC206760 | P08684 | Cytochrome P450 3A4 | CYP3A4 | 31623 | nM | Potency |
TKC206760 | Q9NPD5 | Solute carrier organic anion transporter family member 1B3 | SLCO1B3 | 60 | % | Inhibition |
TKC206760 | Q9Y6L6 | Solute carrier organic anion transporter family member 1B1 | SLCO1B1 | 7 | % | Inhibition |
TKC206760 | O95398 | Rap guanine nucleotide exchange factor 3 | RAPGEF3 | 50119 | nM | Potency |
TKC206760 | P53350 | Serine/threonine-protein kinase PLK1 | PLK1 | 21192 | nM | Potency |
TKC206760 | Q16236 | Nuclear factor erythroid 2-related factor 2 | NFE2L2 | 19331 | nM | Potency |
TKC206760 | P19838 | Nuclear factor NF-kappa-B p105 subunit | NFKB1 | 50119 | nM | Potency |
TKC206760 | O75164 | Lysine-specific demethylase 4A | KDM4A | 79433 | nM | Potency |
TKC206760 | P27695 | DNA-(apurinic or apyrimidinic site) endonuclease | APEX1 | 39811 | nM | Potency |
TKC206760 | Q9UBT6 | DNA polymerase kappa | POLK | 39811 | nM | Potency |
TKC206760 | Q9UNA4 | DNA polymerase iota | POLI | 794 | nM | Potency |
TKC206760 | O75496 | Geminin | GMNN | 10323 | nM | Potency |
TKC206760 | P37840 | Alpha-synuclein | SNCA | 5012 | nM | Potency |
TKC206760 | P38398 | Breast cancer type 1 susceptibility protein | BRCA1 | 39811 | nM | Potency |
TKC206760 | O94782 | Ubiquitin carboxyl-terminal hydrolase 1 | USP1 | 56234 | nM | Potency |
TKC206760 | P39748 | Flap endonuclease 1 | FEN1 | 28184 | nM | Potency |
TKC206760 | P03372 | Estrogen receptor | ESR1 | 25119 | nM | Potency |
TKC206760 | P04150 | Glucocorticoid receptor | NR3C1 | 39811 | nM | Potency |
TKC206760 | P0DTD1 | Replicase polyprotein 1ab | rep | 14 | % | Inhibition |
TKC206760 | P28482 | Mitogen-activated protein kinase 1 | MAPK1 | 39811 | nM | Potency |
TKC206760 | P54132 | Bloom syndrome protein | BLM | 39811 | nM | Potency |
TKC206760 | O15296 | Polyunsaturated fatty acid lipoxygenase ALOX15B | ALOX15B | 22387 | nM | Potency |
TKC206760 | O97447 | Putative fructose-1,6-bisphosphate aldolase | fba | 17741 | nM | Potency |
TKC206760 | P55210 | Caspase-7 | CASP7 | 12589 | nM | Potency |
TKC206760 | Q92830 | Histone acetyltransferase KAT2A | KAT2A | 15849 | nM | Potency |
TKC206760 | Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | HSD17B10 | 39811 | nM | Potency |
TKC206760 | Q9F4F7 | 4'-phosphopantetheinyl transferase ffp | ffp | 28184 | nM | Potency |
TKC206760 | P10828 | Thyroid hormone receptor beta | THRB | 22387 | nM | Potency |
TKC206760 | Q16665 | Hypoxia-inducible factor 1-alpha | HIF1A | 50119 | nM | Potency |
TKC206760 | P37231 | Peroxisome proliferator-activated receptor gamma | PPARG | 17783 | nM | Potency |
TKC206760 | P10809 | 60 kDa heat shock protein, mitochondrial | HSPD1 | 10000 | nM | IC50 |
TKC206760 | P10809 | 60 kDa heat shock protein, mitochondrial | HSPD1 | 10000 | nM | IC50 |
TKC206760 | P02545 | Prelamin-A/C | LMNA | 1413 | nM | Potency |
TKC206760 | Q03181 | Peroxisome proliferator-activated receptor delta | PPARD | 35481 | nM | Potency |
TKC206760 | P15917 | Lethal factor | lef | 5012 | nM | Potency |
TKC206760 | P19793 | Retinoic acid receptor RXR-alpha | RXRA | 28184 | nM | Potency |
TKC206760 | O75604 | Ubiquitin carboxyl-terminal hydrolase 2 | USP2 | 3162 | nM | Potency |
TKC206760 | P04637 | Cellular tumor antigen p53 | TP53 | 31623 | nM | Potency |
TKC206760 | P04637 | Cellular tumor antigen p53 | TP53 | 15000 | nM | Kd |
TKC206760 | P16473 | Thyrotropin receptor | TSHR | 39811 | nM | Potency |
TKC206760 | P10145 | Interleukin-8 | CXCL8 | 74978 | nM | Potency |
TKC206760 | P51449 | Nuclear receptor ROR-gamma | RORC | 74978 | nM | Potency |
TKC206760 | O15439 | ATP-binding cassette sub-family C member 4 | ABCC4 | 68 | % | Activity |
TKC206760 | O60218 | Aldo-keto reductase family 1 member B10 | AKR1B10 | 15 | nM | Ki |
TKC206760 | P15121 | Aldo-keto reductase family 1 member B1 | AKR1B1 | 6900 | nM | IC50 |
TKC206760 | Q96RI1 | Bile acid receptor | NR1H4 | 100000 | nM | EC50 |
TKC206760 | Q96RI1 | Bile acid receptor | NR1H4 | 18 | nM | IC50 |
TKC206760 | Q96RI1 | Bile acid receptor | NR1H4 | 20000 | nM | EC50 |
TKC206760 | Q96RI1 | Bile acid receptor | NR1H4 | 6700 | nM | EC50 |
TKC206760 | Q548M1 | 60 kDa chaperonin | groL | >250000 | nM | IC50 |
TKC206760 | Q548M1 | 60 kDa chaperonin | groL | 16000 | nM | IC50 |
TKC206760 | P54855 | UDP-glucuronosyltransferase 2B15 | UGT2B15 | 0 | pm/min/mg | Activity |
TKC206760 | Q9HAW8 | UDP-glucuronosyltransferase 1A10 | UGT1A10 | 0 | pm/min/mg | Activity |
TKC206760 | Q9HAW9 | UDP-glucuronosyltransferase 1A8 | UGT1A8 | 11 | pm/min/mg | Activity |
TKC206760 | Q9GZU7 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | CTDSP1 | 4823 | nM | IC50 |
TKC206760 | Q9GZU7 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | CTDSP1 | 4823 | nM | IC50 |
TKC206760 | O75469 | Nuclear receptor subfamily 1 group I member 2 | NR1I2 | 19 | % | max activation |
TKC206760 | Q11201 | CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 | ST3GAL1 | 21000 | nM | IC50 |
TKC206760 | Q16762 | Thiosulfate sulfurtransferase | TST | >100000 | nM | IC50 |
TKC206760 | Q16762 | Thiosulfate sulfurtransferase | TST | >100000 | nM | IC50 |
TKC206760 | Q8TDU6 | G-protein coupled bile acid receptor 1 | GPBAR1 | 680 | nM | EC50 |
TKC206760 | Q8TDU6 | G-protein coupled bile acid receptor 1 | GPBAR1 | 580 | nM | EC50 |
TKC206760 | Q8TDU6 | G-protein coupled bile acid receptor 1 | GPBAR1 | 5600 | nM | EC50 |
TKC206760 | Q8TDU6 | G-protein coupled bile acid receptor 1 | GPBAR1 | 5000 | nM | EC50 |
TKC206760 | Q8TDU6 | G-protein coupled bile acid receptor 1 | GPBAR1 | 730 | nM | EC50 |
TKC206760 | P03070 | Large T antigen | 26100 | nM | IC50 | |
TKC206760 | P06133 | UDP-glucuronosyltransferase 2B4 | UGT2B4 | 0 | pm/min/mg | Activity |
TKC206760 | Q14973 | Sodium/bile acid cotransporter | SLC10A1 | 63 | % | Activity |
TKC206760 | O75795 | UDP-glucuronosyltransferase 2B17 | UGT2B17 | 0 | pm/min/mg | Activity |
TKC206760 | P29317 | Ephrin type-A receptor 2 | EPHA2 | 50000 | nM | IC50 |
TKC206760 | Q03145 | Ephrin type-A receptor 2 | Epha2 | 57000 | nM | IC50 |
TKC206760 | Q03145 | Ephrin type-A receptor 2 | Epha2 | 79000 | nM | IC50 |
Uniport ID | Uniport Name | ICD-11 |
---|---|---|
Q12809 | KCNH2_HUMAN | Heart failure [ICD-11: BD10-BD1Z] |
Q12809 | KCNH2_HUMAN | Sleep-wake disorder [ICD-11: 7A00-7B2Z] |
Q12809 | KCNH2_HUMAN | Malaria [ICD-11: 1F40-1F45] |
Q12809 | KCNH2_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
Q12809 | KCNH2_HUMAN | Pain [ICD-11: MG30-MG3Z] |
Q12809 | KCNH2_HUMAN | Cardiac arrhythmia [ICD-11: BC9Z] |
Q12809 | KCNH2_HUMAN | Angina pectoris [ICD-11: BA40] |
Q12809 | KCNH2_HUMAN | Genetic cardiac arrhythmia [ICD-11: BC65] |
Q12809 | KCNH2_HUMAN | Ovarian cancer [ICD-11: 2C73] |
P10636 | TAU_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 | TAU_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P10636 | TAU_HUMAN | Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 | TAU_HUMAN | Choreiform disorder [ICD-11: 8A01] |
P10636 | TAU_HUMAN | Parkinsonism [ICD-11: 8A00] |
P10636 | TAU_HUMAN | Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 | TAU_HUMAN | Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 | VDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P11473 | VDR_HUMAN | Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 | VDR_HUMAN | Hyper-parathyroidism [ICD-11: 5A51] |
P11473 | VDR_HUMAN | Hypo-parathyroidism [ICD-11: 5A50] |
P11473 | VDR_HUMAN | Mineral deficiency [ICD-11: 5B5K] |
P11473 | VDR_HUMAN | Psoriasis [ICD-11: EA90] |
P11473 | VDR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 | VDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P11473 | VDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 | VDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P11473 | VDR_HUMAN | Prostate disease [ICD-11: GA91] |
P11473 | VDR_HUMAN | Abnormal micturition [ICD-11: MF50] |
P11473 | VDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 | VDR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 | VDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P11473 | VDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P11473 | VDR_HUMAN | Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 | VDR_HUMAN | Hyper-parathyroidism [ICD-11: 5A51] |
P11473 | VDR_HUMAN | Hypo-parathyroidism [ICD-11: 5A50] |
P11473 | VDR_HUMAN | Mineral deficiency [ICD-11: 5B5K] |
P11473 | VDR_HUMAN | Psoriasis [ICD-11: EA90] |
P11473 | VDR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 | VDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P11473 | VDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 | VDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P11473 | VDR_HUMAN | Prostate disease [ICD-11: GA91] |
P11473 | VDR_HUMAN | Abnormal micturition [ICD-11: MF50] |
P11473 | VDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 | VDR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 | VDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P11473 | VDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P11473 | VDR_HUMAN | Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 | VDR_HUMAN | Hyper-parathyroidism [ICD-11: 5A51] |
P11473 | VDR_HUMAN | Hypo-parathyroidism [ICD-11: 5A50] |
P11473 | VDR_HUMAN | Mineral deficiency [ICD-11: 5B5K] |
P11473 | VDR_HUMAN | Psoriasis [ICD-11: EA90] |
P11473 | VDR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 | VDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P11473 | VDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 | VDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P11473 | VDR_HUMAN | Prostate disease [ICD-11: GA91] |
P11473 | VDR_HUMAN | Abnormal micturition [ICD-11: MF50] |
P11473 | VDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 | VDR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 | VDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P18031 | PTN1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P18031 | PTN1_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P18031 | PTN1_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P18031 | PTN1_HUMAN | Obesity [ICD-11: 5B80-5B81] |
P18031 | PTN1_HUMAN | Ophthalmic devices/implants/grafts injury [ICD-11: PK97] |
P18031 | PTN1_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P18031 | PTN1_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
P18031 | PTN1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P17706 | PTN2_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Atopic eczema [ICD-11: EA80] |
P08684 | CP3A4_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
O95398 | RPGF3_HUMAN | Epidermal dysplasias [ICD-11: EK90] |
P53350 | PLK1_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P53350 | PLK1_HUMAN | Myelodysplastic syndrome [ICD-11: 2A37] |
P53350 | PLK1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P53350 | PLK1_HUMAN | Prostate cancer [ICD-11: 2C82] |
P53350 | PLK1_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P53350 | PLK1_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P53350 | PLK1_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
P53350 | PLK1_HUMAN | Nasopharyngeal cancer [ICD-11: 2B6B] |
P53350 | PLK1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16236 | NF2L2_HUMAN | Ataxic disorder [ICD-11: 8A03] |
Q16236 | NF2L2_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 | NF2L2_HUMAN | Glaucoma [ICD-11: 9C61] |
Q16236 | NF2L2_HUMAN | Lung cancer [ICD-11: 2C25] |
Q16236 | NF2L2_HUMAN | Macular degeneration [ICD-11: 9B75] |
Q16236 | NF2L2_HUMAN | Melanoma [ICD-11: 2C30] |
Q16236 | NF2L2_HUMAN | Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 | NF2L2_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
Q16236 | NF2L2_HUMAN | Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 | NF2L2_HUMAN | Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 | NF2L2_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 | NF2L2_HUMAN | Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 | NF2L2_HUMAN | Motor neuron disease [ICD-11: 8B60] |
Q16236 | NF2L2_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P19838 | NFKB1_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P19838 | NFKB1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P19838 | NFKB1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P27695 | APEX1_HUMAN | Retinopathy [ICD-11: 9B71] |
P27695 | APEX1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P27695 | APEX1_HUMAN | Ocular cancer [ICD-11: 2D00-2D07] |
P27695 | APEX1_HUMAN | Brain cancer [ICD-11: 2A00] |
P27695 | APEX1_HUMAN | Melanoma [ICD-11: 2C30] |
P37840 | SYUA_HUMAN | Parkinsonism [ICD-11: 8A00] |
P37840 | SYUA_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P37840 | SYUA_HUMAN | Autonomic nervous system disorder [ICD-11: 8D87] |
O94782 | UBP1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P03372 | ESR1_HUMAN | Acne vulgaris [ICD-11: ED80] |
P03372 | ESR1_HUMAN | Acquired prion disease [ICD-11: 8E01] |
P03372 | ESR1_HUMAN | Adrenal cancer [ICD-11: 2D11] |
P03372 | ESR1_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P03372 | ESR1_HUMAN | Contraceptive management [ICD-11: QA21] |
P03372 | ESR1_HUMAN | Dyspareunia [ICD-11: GA12] |
P03372 | ESR1_HUMAN | Female infertility [ICD-11: GA31] |
P03372 | ESR1_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P03372 | ESR1_HUMAN | Male infertility [ICD-11: GB04] |
P03372 | ESR1_HUMAN | Menopausal disorder [ICD-11: GA30] |
P03372 | ESR1_HUMAN | Menstrual cycle bleeding disorder [ICD-11: GA20] |
P03372 | ESR1_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P03372 | ESR1_HUMAN | Pituitary gland disorder [ICD-11: 5A60-5A61] |
P03372 | ESR1_HUMAN | Skeletal anomaly [ICD-11: LD24] |
P03372 | ESR1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P03372 | ESR1_HUMAN | Vaginitis [ICD-11: GA02] |
P03372 | ESR1_HUMAN | Virus infection [ICD-11: 1A24-1D9Z] |
P03372 | ESR1_HUMAN | Endometriosis [ICD-11: GA10] |
P03372 | ESR1_HUMAN | Female genital tract noninflammatory disorder [ICD-11: GA1Y] |
P03372 | ESR1_HUMAN | Female pelvic pain [ICD-11: GA34] |
P03372 | ESR1_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
P03372 | ESR1_HUMAN | Breast in situ carcinoma [ICD-11: 2E65] |
P03372 | ESR1_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
P03372 | ESR1_HUMAN | Prostate cancer [ICD-11: 2C82] |
P03372 | ESR1_HUMAN | Brain cancer [ICD-11: 2A00] |
P03372 | ESR1_HUMAN | Metastatic tumour [ICD-11: 2D50-2E2Z] |
P03372 | ESR1_HUMAN | Irregularities [ICD-11: N.A.] |
P03372 | ESR1_HUMAN | Trematode disease [ICD-11: 1F8Y] |
P03372 | ESR1_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P03372 | ESR1_HUMAN | Eye disorder [ICD-11: 9A01-9A0Z] |
P03372 | ESR1_HUMAN | Dissociative neurological symptom disorder [ICD-11: 6B60] |
P03372 | ESR1_HUMAN | Thrombocytopenia [ICD-11: 3B64] |
P03372 | ESR1_HUMAN | Atrophy [ICD-11: 9A2Y-9C40] |
P03372 | ESR1_HUMAN | Joint pain [ICD-11: ME82] |
P03372 | ESR1_HUMAN | Sexual dysfunction [ICD-11: HA00-HA01] |
P03372 | ESR1_HUMAN | Leukaemia [ICD-11: 2A60-2B33] |
P04150 | GCR_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P04150 | GCR_HUMAN | Indeterminate colitis [ICD-11: DD72] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Adaptive immunity immunodeficiency [ICD-11: 4A01] |
P04150 | GCR_HUMAN | Adrenogenital disorder [ICD-11: 5A71] |
P04150 | GCR_HUMAN | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P04150 | GCR_HUMAN | Asthma [ICD-11: CA23] |
P04150 | GCR_HUMAN | Atopic eczema [ICD-11: EA80] |
P04150 | GCR_HUMAN | Chronic obstructive pulmonary disease [ICD-11: CA22] |
P04150 | GCR_HUMAN | Cushing syndrome [ICD-11: 5A70] |
P04150 | GCR_HUMAN | Eczema [ICD-11: EA80-EA89] |
P04150 | GCR_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P04150 | GCR_HUMAN | Muscular dystrophy [ICD-11: 8C70] |
P04150 | GCR_HUMAN | Oesophagitis [ICD-11: DA24] |
P04150 | GCR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P04150 | GCR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P04150 | GCR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 | GCR_HUMAN | Spine/trunk injury [ICD-11: ND51] |
P04150 | GCR_HUMAN | Vasomotor/allergic rhinitis [ICD-11: CA08] |
P04150 | GCR_HUMAN | Herpes simplex infection [ICD-11: 1F00] |
P04150 | GCR_HUMAN | Otitis externa [ICD-11: AA00-AA13] |
P04150 | GCR_HUMAN | Substance abuse [ICD-11: 6C40] |
P04150 | GCR_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P04150 | GCR_HUMAN | Depression [ICD-11: 6A70-6A7Z] |
P04150 | GCR_HUMAN | Mood disorder [ICD-11: 6A60-6E23] |
P04150 | GCR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 | GCR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P04150 | GCR_HUMAN | Retinopathy [ICD-11: 9B71] |
P04150 | GCR_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P28482 | MK01_HUMAN | Melanoma [ICD-11: 2C30] |
P28482 | MK01_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P28482 | MK01_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P28482 | MK01_HUMAN | Arteries/arterioles disorder [ICD-11: BD52] |
P28482 | MK01_HUMAN | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P28482 | MK01_HUMAN | Transplant rejection [ICD-11: NE84] |
P28482 | MK01_HUMAN | Mature T-cell lymphoma [ICD-11: 2A90] |
P28482 | MK01_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P55210 | CASP7_HUMAN | Cystic fibrosis [ICD-11: CA25] |
P10828 | THB_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
P10828 | THB_HUMAN | Hypo-thyroidism [ICD-11: 5A00] |
P10828 | THB_HUMAN | Inborn lipid metabolism error [ICD-11: 5C52] |
P10828 | THB_HUMAN | Skin postprocedural disorder [ICD-11: EL8Y] |
P10828 | THB_HUMAN | Thyrotoxicosis [ICD-11: 5A02] |
Q16665 | HIF1A_HUMAN | Adrenomedullary hyperfunction [ICD-11: 5A75] |
Q16665 | HIF1A_HUMAN | Brain cancer [ICD-11: 2A00] |
Q16665 | HIF1A_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
Q16665 | HIF1A_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 | HIF1A_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
P37231 | PPARG_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
P37231 | PPARG_HUMAN | Sjogren syndrome [ICD-11: 4A43] |
P37231 | PPARG_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 | PPARG_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P37231 | PPARG_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P37231 | PPARG_HUMAN | Obesity [ICD-11: 5B80-5B81] |
P37231 | PPARG_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 | PPARG_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
P37231 | PPARG_HUMAN | Glaucoma [ICD-11: 9C61] |
P37231 | PPARG_HUMAN | Inborn lipid metabolism error [ICD-11: 5C52] |
P37231 | PPARG_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P37231 | PPARG_HUMAN | Gout [ICD-11: FA25] |
P37231 | PPARG_HUMAN | Indeterminate colitis [ICD-11: DD72] |
P37231 | PPARG_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P37231 | PPARG_HUMAN | Nicotine use disorder [ICD-11: 6C4A] |
P37231 | PPARG_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
P37231 | PPARG_HUMAN | Opioid use disorder [ICD-11: 6C43] |
P37231 | PPARG_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
P37231 | PPARG_HUMAN | Idiopathic interstitial pneumonitis [ICD-11: CB03] |
P37231 | PPARG_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
P10809 | CH60_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
P10809 | CH60_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
Q03181 | PPARD_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q03181 | PPARD_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q03181 | PPARD_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q03181 | PPARD_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q03181 | PPARD_HUMAN | Obesity [ICD-11: 5B80-5B81] |
Q03181 | PPARD_HUMAN | Alzheimer disease [ICD-11: 8A20] |
Q03181 | PPARD_HUMAN | Dyslipidemia [ICD-11: 5C80-5C81] |
Q03181 | PPARD_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 | PPARD_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
Q03181 | PPARD_HUMAN | Central nervous system disease [ICD-11: 8A04-8D87] |
P15917 | LEF_BACAN | Sepsis [ICD-11: 1G40-1G41] |
P15917 | LEF_BACAN | Corneal disease [ICD-11: 9A76-9A78] |
P19793 | RXRA_HUMAN | Kaposi sarcoma [ICD-11: 2B57] |
P19793 | RXRA_HUMAN | Mycosis fungoides [ICD-11: 2B01] |
O75604 | UBP2_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P04637 | P53_HUMAN | Arterial occlusive disease [ICD-11: BD40] |
P04637 | P53_HUMAN | Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] |
P04637 | P53_HUMAN | Metastatic liver/bile duct neoplasm [ICD-11: 2D80] |
P04637 | P53_HUMAN | Transplant rejection [ICD-11: NE84] |
P04637 | P53_HUMAN | Ovarian dysfunction [ICD-11: 5A80] |
P04637 | P53_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 | P53_HUMAN | Bladder cancer [ICD-11: 2C94] |
P04637 | P53_HUMAN | Brain cancer [ICD-11: 2A00] |
P04637 | P53_HUMAN | Colorectal cancer [ICD-11: 2B91] |
P04637 | P53_HUMAN | Esophageal cancer [ICD-11: 2B70] |
P04637 | P53_HUMAN | Head and neck cancer [ICD-11: 2D42] |
P04637 | P53_HUMAN | Mature B-cell leukaemia [ICD-11: 2A82] |
P04637 | P53_HUMAN | Myelodysplastic syndrome [ICD-11: 2A37] |
P04637 | P53_HUMAN | Ovarian cancer [ICD-11: 2C73] |
P04637 | P53_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P04637 | P53_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 | P53_HUMAN | Stomach cancer [ICD-11: 2B72] |
P04637 | P53_HUMAN | Cervical cancer [ICD-11: 2C77] |
P04637 | P53_HUMAN | Endometrial cancer [ICD-11: 2C76] |
P04637 | P53_HUMAN | Fallopian tube cancer [ICD-11: 2C74] |
P04637 | P53_HUMAN | Liposarcoma [ICD-11: 2B59] |
P04637 | P53_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P04637 | P53_HUMAN | Peritoneal cancer [ICD-11: 2C51] |
P04637 | P53_HUMAN | Toxicity [ICD-11: N.A.] |
P04637 | P53_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 | P53_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 | P53_HUMAN | Kidney failure [ICD-11: GB60-GB6Z] |
P04637 | P53_HUMAN | Hearing disorder [ICD-11: AB50-AB57] |
P04637 | P53_HUMAN | Arterial occlusive disease [ICD-11: BD40] |
P04637 | P53_HUMAN | Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] |
P04637 | P53_HUMAN | Metastatic liver/bile duct neoplasm [ICD-11: 2D80] |
P04637 | P53_HUMAN | Transplant rejection [ICD-11: NE84] |
P04637 | P53_HUMAN | Ovarian dysfunction [ICD-11: 5A80] |
P04637 | P53_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 | P53_HUMAN | Bladder cancer [ICD-11: 2C94] |
P04637 | P53_HUMAN | Brain cancer [ICD-11: 2A00] |
P04637 | P53_HUMAN | Colorectal cancer [ICD-11: 2B91] |
P04637 | P53_HUMAN | Esophageal cancer [ICD-11: 2B70] |
P04637 | P53_HUMAN | Head and neck cancer [ICD-11: 2D42] |
P04637 | P53_HUMAN | Mature B-cell leukaemia [ICD-11: 2A82] |
P04637 | P53_HUMAN | Myelodysplastic syndrome [ICD-11: 2A37] |
P04637 | P53_HUMAN | Ovarian cancer [ICD-11: 2C73] |
P04637 | P53_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P04637 | P53_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 | P53_HUMAN | Stomach cancer [ICD-11: 2B72] |
P04637 | P53_HUMAN | Cervical cancer [ICD-11: 2C77] |
P04637 | P53_HUMAN | Endometrial cancer [ICD-11: 2C76] |
P04637 | P53_HUMAN | Fallopian tube cancer [ICD-11: 2C74] |
P04637 | P53_HUMAN | Liposarcoma [ICD-11: 2B59] |
P04637 | P53_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P04637 | P53_HUMAN | Peritoneal cancer [ICD-11: 2C51] |
P04637 | P53_HUMAN | Toxicity [ICD-11: N.A.] |
P04637 | P53_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 | P53_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 | P53_HUMAN | Kidney failure [ICD-11: GB60-GB6Z] |
P04637 | P53_HUMAN | Hearing disorder [ICD-11: AB50-AB57] |
P16473 | TSHR_HUMAN | Hypo-thyroidism [ICD-11: 5A00] |
P16473 | TSHR_HUMAN | Thyroid cancer [ICD-11: 2D10] |
P10145 | IL8_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P10145 | IL8_HUMAN | COVID-19 [ICD-11: 1D6Y] |
P10145 | IL8_HUMAN | Melanoma [ICD-11: 2C30] |
P10145 | IL8_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10145 | IL8_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
P51449 | RORG_HUMAN | Autoimmune disease [ICD-11: 4A40-4A45] |
P51449 | RORG_HUMAN | Lung cancer [ICD-11: 2C25] |
P51449 | RORG_HUMAN | Psoriasis [ICD-11: EA90] |
P51449 | RORG_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P51449 | RORG_HUMAN | Crohn disease [ICD-11: DD70] |
P51449 | RORG_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P51449 | RORG_HUMAN | Arterial occlusive disease [ICD-11: BD40] |
P51449 | RORG_HUMAN | Liver cancer [ICD-11: 2C12] |
P51449 | RORG_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P15121 | ALDR_HUMAN | Neuropathy [ICD-11: 8C0Z] |
P15121 | ALDR_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P15121 | ALDR_HUMAN | Rheumatoid arthritis [ICD-11: FA20] |
P15121 | ALDR_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P15121 | ALDR_HUMAN | Thrombosis [ICD-11: DB61-GB90] |
P15121 | ALDR_HUMAN | Cataract [ICD-11: 9B10] |
P15121 | ALDR_HUMAN | Glaucoma [ICD-11: 9C61] |
P15121 | ALDR_HUMAN | Schizophrenia [ICD-11: 6A20] |
P15121 | ALDR_HUMAN | Gout [ICD-11: FA25] |
P15121 | ALDR_HUMAN | Head and neck cancer [ICD-11: 2D42] |
Q96RI1 | NR1H4_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 | NR1H4_HUMAN | Cholelithiasis [ICD-11: DC11] |
Q96RI1 | NR1H4_HUMAN | Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 | NR1H4_HUMAN | Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 | NR1H4_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 | NR1H4_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 | NR1H4_HUMAN | Chronic kidney disease [ICD-11: GB61] |
Q96RI1 | NR1H4_HUMAN | Skeletal anomaly [ICD-11: LD24] |
Q96RI1 | NR1H4_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 | NR1H4_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 | NR1H4_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q96RI1 | NR1H4_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 | NR1H4_HUMAN | Cholelithiasis [ICD-11: DC11] |
Q96RI1 | NR1H4_HUMAN | Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 | NR1H4_HUMAN | Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 | NR1H4_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 | NR1H4_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 | NR1H4_HUMAN | Chronic kidney disease [ICD-11: GB61] |
Q96RI1 | NR1H4_HUMAN | Skeletal anomaly [ICD-11: LD24] |
Q96RI1 | NR1H4_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 | NR1H4_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 | NR1H4_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q96RI1 | NR1H4_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 | NR1H4_HUMAN | Cholelithiasis [ICD-11: DC11] |
Q96RI1 | NR1H4_HUMAN | Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 | NR1H4_HUMAN | Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 | NR1H4_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 | NR1H4_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 | NR1H4_HUMAN | Chronic kidney disease [ICD-11: GB61] |
Q96RI1 | NR1H4_HUMAN | Skeletal anomaly [ICD-11: LD24] |
Q96RI1 | NR1H4_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 | NR1H4_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 | NR1H4_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q96RI1 | NR1H4_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 | NR1H4_HUMAN | Cholelithiasis [ICD-11: DC11] |
Q96RI1 | NR1H4_HUMAN | Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 | NR1H4_HUMAN | Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 | NR1H4_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 | NR1H4_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 | NR1H4_HUMAN | Chronic kidney disease [ICD-11: GB61] |
Q96RI1 | NR1H4_HUMAN | Skeletal anomaly [ICD-11: LD24] |
Q96RI1 | NR1H4_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 | NR1H4_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 | NR1H4_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q8TDU6 | GPBAR_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q8TDU6 | GPBAR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q8TDU6 | GPBAR_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q8TDU6 | GPBAR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q8TDU6 | GPBAR_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q8TDU6 | GPBAR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q8TDU6 | GPBAR_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q8TDU6 | GPBAR_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
Q8TDU6 | GPBAR_HUMAN | Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q8TDU6 | GPBAR_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q14973 | NTCP_HUMAN | Hepatitis virus infection [ICD-11: 1E50-1E51] |
Q14973 | NTCP_HUMAN | Autoimmune liver disease [ICD-11: DB96] |
Q14973 | NTCP_HUMAN | Gallbladder/bile ducts/liver structural developmental anomaly [ICD-11: LB20] |
Q14973 | NTCP_HUMAN | Inborn porphyrin/heme metabolism error [ICD-11: 5C58] |
P29317 | EPHA2_HUMAN | Brain cancer [ICD-11: 2A00] |
P29317 | EPHA2_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |